Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1970 Feb;33(1):1–6. doi: 10.1136/jnnp.33.1.1

The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa.

G Curzon, R B Godwin-Austen, E B Tomlinson, B D Kantamaneni
PMCID: PMC493400  PMID: 5418176

Full text

PDF
1

Images in this article

3Image
on p.3

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ANDEN N. E., CARLSSON A., DAHLSTROEM A., FUXE K., HILLARP N. A., LARSSON K. DEMONSTRATION AND MAPPING OUT OF NIGRO-NEOSTRIATAL DOPAMINE NEURONS. Life Sci. 1964 Jun;3:523–530. doi: 10.1016/0024-3205(64)90161-4. [DOI] [PubMed] [Google Scholar]
  2. ANDEN N. E., ROOS B. E., WERDINIUS B. On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 1963 Jul;(7):448–458. doi: 10.1016/0024-3205(63)90132-2. [DOI] [PubMed] [Google Scholar]
  3. Bartholini G., Pletscher A. Cerebral accumulation and metabolism of C14-dopa after selective inhibition of peripheral decarboxylase. J Pharmacol Exp Ther. 1968 May;161(1):14–20. [PubMed] [Google Scholar]
  4. Bernheimer H., Hornykiewicz O. Herabgesetzte Konzentration der Homovanillinsäure im Gehirn von parkinsonkranken Menschen als Ausdruck der Störung des zentralen Dopaminstoffwechsels. Klin Wochenschr. 1965 Jul 1;43(13):711–715. doi: 10.1007/BF01707066. [DOI] [PubMed] [Google Scholar]
  5. Calne D. B., Stern G. M., Laurence D. R., Sharkey J., Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. doi: 10.1016/s0140-6736(69)91751-6. [DOI] [PubMed] [Google Scholar]
  6. Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
  7. Cotzias G. C., Van Woert M. H., Schiffer L. M. Aromatic amino acids and modification of parkinsonism. N Engl J Med. 1967 Feb 16;276(7):374–379. doi: 10.1056/NEJM196702162760703. [DOI] [PubMed] [Google Scholar]
  8. DAGIRMANJIAN R., LAVERTY R., MANTEGAZZINI P., SHARMAN D. F., VOGT M. Chemical and physiological changes produced by arterial infusion of dihydroxyphenylalanine into one cerebral hemisphere of the cat. J Neurochem. 1963 Mar;10:177–182. doi: 10.1111/j.1471-4159.1963.tb09480.x. [DOI] [PubMed] [Google Scholar]
  9. Da Prada M., Pletscher A. Acceleration of the cerebral dopamine turnover by chlorpromazine. Experientia. 1966 Jul 15;22(7):465–466. doi: 10.1007/BF01900988. [DOI] [PubMed] [Google Scholar]
  10. EHRINGER H., HORNYKIEWICZ O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system]. Klin Wochenschr. 1960 Dec 15;38:1236–1239. doi: 10.1007/BF01485901. [DOI] [PubMed] [Google Scholar]
  11. GREENFIELD J. G., BOSANQUET F. D. The brain-stem lesions in Parkinsonism. J Neurol Neurosurg Psychiatry. 1953 Nov;16(4):213–226. doi: 10.1136/jnnp.16.4.213. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Glowinski J., Iversen L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966 Aug;13(8):655–669. doi: 10.1111/j.1471-4159.1966.tb09873.x. [DOI] [PubMed] [Google Scholar]
  13. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  14. HORNYKIEWICZ O. [The tropical localization and content of noradrenalin and dopamine (3-hydroxytyramine) in the substantia nigra of normal persons and patients with Parkinson's disease]. Wien Klin Wochenschr. 1963 May 3;75:309–312. [PubMed] [Google Scholar]
  15. KUNTZMAN R., SHORE P. A., BOGDANSKI D., BRODIE B. B. Microanalytical procedures for fluorometric assay of brain DOPA-5HTP decarboxylase, norepinephrine and serotonin, and a detailed mapping of decarboxylase activity in brain. J Neurochem. 1961 Feb;6:226–232. doi: 10.1111/j.1471-4159.1961.tb13469.x. [DOI] [PubMed] [Google Scholar]
  16. Murphy G. F., Robinson D., Sharman D. F. The effect of tropolone on the formation of 3,4-dihydroxyphenylacetic acid and 4-hydroxy-3-methoxyphenylacetic acid in the brain of the mouse. Br J Pharmacol. 1969 May;36(1):107–115. doi: 10.1111/j.1476-5381.1969.tb08308.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Olsson R., Roos B. E. Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature. 1968 Aug 3;219(5153):502–503. doi: 10.1038/219502a0. [DOI] [PubMed] [Google Scholar]
  18. POIRIER L. J., SOURKES T. L. INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM. Brain. 1965 Mar;88:181–192. doi: 10.1093/brain/88.1.181. [DOI] [PubMed] [Google Scholar]
  19. Yahr M. D., Duvoisin R. C., Hoehn M. M., Schear M. J., Barrett R. E. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism. Trans Am Neurol Assoc. 1968;93:56–63. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES